1 Report Overview 1.1 Study Scope 1.2 Market Analysis by Type 1.2.1 Global Macular Degeneration (AMD) and Other Retinal Diseases Market Size Growth Rate by Type: 2016 VS 2021 VS 2027 1.2.2 Macular Degeneration 1.2.3 Diabetic Macular Edema 1.2.4 Diabetic Retinopathy(DR) 1.2.5 Retinal Vein Occlusion 1.2.6 Wet Age-Related Macular Degeneration (wAMD) 1.2.7 Dry Age-Related Macular Degeneration (dAMD) 1.2.8 Other 1.3 Market by Application 1.3.1 Global Macular Degeneration (AMD) and Other Retinal Diseases Market Share by Application: 2016 VS 2021 VS 2027 1.3.2 Hospital 1.3.3 Clinic 1.3.4 Other 1.4 Study Objectives 1.5 Years Considered 2 Global Growth Trends 2.1 Global Macular Degeneration (AMD) and Other Retinal Diseases Market Perspective (2016-2027) 2.2 Macular Degeneration (AMD) and Other Retinal Diseases Growth Trends by Regions 2.2.1 Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Regions: 2016 VS 2021 VS 2027 2.2.2 Macular Degeneration (AMD) and Other Retinal Diseases Historic Market Share by Regions (2016-2021) 2.2.3 Macular Degeneration (AMD) and Other Retinal Diseases Forecasted Market Size by Regions (2022-2027) 2.3 Macular Degeneration (AMD) and Other Retinal Diseases Industry Dynamic 2.3.1 Macular Degeneration (AMD) and Other Retinal Diseases Market Trends 2.3.2 Macular Degeneration (AMD) and Other Retinal Diseases Market Drivers 2.3.3 Macular Degeneration (AMD) and Other Retinal Diseases Market Challenges 2.3.4 Macular Degeneration (AMD) and Other Retinal Diseases Market Restraints 3 Competition Landscape by Key Players 3.1 Global Top Macular Degeneration (AMD) and Other Retinal Diseases Players by Revenue 3.1.1 Global Top Macular Degeneration (AMD) and Other Retinal Diseases Players by Revenue (2016-2021) 3.1.2 Global Macular Degeneration (AMD) and Other Retinal Diseases Revenue Market Share by Players (2016-2021) 3.2 Global Macular Degeneration (AMD) and Other Retinal Diseases Market Share by Company Type (Tier 1, Tier 2 and Tier 3) 3.3 Players Covered: Ranking by Macular Degeneration (AMD) and Other Retinal Diseases Revenue 3.4 Global Macular Degeneration (AMD) and Other Retinal Diseases Market Concentration Ratio 3.4.1 Global Macular Degeneration (AMD) and Other Retinal Diseases Market Concentration Ratio (CR5 and HHI) 3.4.2 Global Top 10 and Top 5 Companies by Macular Degeneration (AMD) and Other Retinal Diseases Revenue in 2020 3.5 Macular Degeneration (AMD) and Other Retinal Diseases Key Players Head office and Area Served 3.6 Key Players Macular Degeneration (AMD) and Other Retinal Diseases Product Solution and Service 3.7 Date of Enter into Macular Degeneration (AMD) and Other Retinal Diseases Market 3.8 Mergers & Acquisitions, Expansion Plans 4 Macular Degeneration (AMD) and Other Retinal Diseases Breakdown Data by Type 4.1 Global Macular Degeneration (AMD) and Other Retinal Diseases Historic Market Size by Type (2016-2021) 4.2 Global Macular Degeneration (AMD) and Other Retinal Diseases Forecasted Market Size by Type (2022-2027) 5 Macular Degeneration (AMD) and Other Retinal Diseases Breakdown Data by Application 5.1 Global Macular Degeneration (AMD) and Other Retinal Diseases Historic Market Size by Application (2016-2021) 5.2 Global Macular Degeneration (AMD) and Other Retinal Diseases Forecasted Market Size by Application (2022-2027) 6 North America 6.1 North America Macular Degeneration (AMD) and Other Retinal Diseases Market Size (2016-2027) 6.2 North America Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Type 6.2.1 North America Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Type (2016-2021) 6.2.2 North America Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Type (2022-2027) 6.2.3 North America Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Type (2016-2027) 6.3 North America Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Application 6.3.1 North America Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Application (2016-2021) 6.3.2 North America Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Application (2022-2027) 6.3.3 North America Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Application (2016-2027) 6.4 North America Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Country 6.4.1 North America Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Country (2016-2021) 6.4.2 North America Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Country (2022-2027) 6.4.3 United States 6.4.3 Canada 7 Europe 7.1 Europe Macular Degeneration (AMD) and Other Retinal Diseases Market Size (2016-2027) 7.2 Europe Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Type 7.2.1 Europe Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Type (2016-2021) 7.2.2 Europe Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Type (2022-2027) 7.2.3 Europe Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Type (2016-2027) 7.3 Europe Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Application 7.3.1 Europe Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Application (2016-2021) 7.3.2 Europe Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Application (2022-2027) 7.3.3 Europe Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Application (2016-2027) 7.4 Europe Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Country 7.4.1 Europe Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Country (2016-2021) 7.4.2 Europe Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Country (2022-2027) 7.4.3 Germany 7.4.4 France 7.4.5 U.K. 7.4.6 Italy 7.4.7 Russia 7.4.8 Nordic 8 Asia-Pacific 8.1 Asia-Pacific Macular Degeneration (AMD) and Other Retinal Diseases Market Size (2016-2027) 8.2 Asia-Pacific Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Type 8.2.1 Asia-Pacific Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Type (2016-2021) 8.2.2 Asia-Pacific Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Type (2022-2027) 8.2.3 Asia-Pacific Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Type (2016-2027) 8.3 Asia-Pacific Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Application 8.3.1 Asia-Pacific Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Application (2016-2021) 8.3.2 Asia-Pacific Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Application (2022-2027) 8.3.3 Asia-Pacific Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Application (2016-2027) 8.4 Asia-Pacific Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Region 8.4.1 Asia-Pacific Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Region (2016-2021) 8.4.2 Asia-Pacific Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Region (2022-2027) 8.4.3 China 8.4.4 Japan 8.4.5 South Korea 8.4.6 Southeast Asia 8.4.7 India 8.4.8 Australia 9 Latin America 9.1 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Market Size (2016-2027) 9.2 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Type 9.2.1 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Type (2016-2021) 9.2.2 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Type (2022-2027) 9.2.3 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Type (2016-2027) 9.3 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Application 9.3.1 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Application (2016-2021) 9.3.2 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Application (2022-2027) 9.3.3 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Application (2016-2027) 9.4 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Country 9.4.1 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Country (2016-2021) 9.4.2 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Country (2022-2027) 9.4.3 Mexico 9.4.4 Brazil 10 Middle East & Africa 10.1 Middle East & Africa Macular Degeneration (AMD) and Other Retinal Diseases Market Size (2016-2027) 10.2 Middle East & Africa Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Type 10.2.1 Middle East & Africa Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Type (2016-2021) 10.2.2 Middle East & Africa Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Type (2022-2027) 10.2.3 Middle East & Africa Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Type (2016-2027) 10.3 Middle East & Africa Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Application 10.3.1 Middle East & Africa Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Application (2016-2021) 10.3.2 Middle East & Africa Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Application (2022-2027) 10.3.3 Middle East & Africa Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Application (2016-2027) 10.4 Middle East & Africa Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Country 10.4.1 Middle East & Africa Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Country (2016-2021) 10.4.2 Middle East & Africa Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Country (2022-2027) 10.4.3 Turkey 10.4.4 Saudi Arabia 10.4.5 UAE 11 Key Players Profiles 11.1 Regeneron Pharmaceuticals 11.1.1 Regeneron Pharmaceuticals Company Details 11.1.2 Regeneron Pharmaceuticals Business Overview 11.1.3 Regeneron Pharmaceuticals Macular Degeneration (AMD) and Other Retinal Diseases Introduction 11.1.4 Regeneron Pharmaceuticals Revenue in Macular Degeneration (AMD) and Other Retinal Diseases Business (2016-2021) 11.1.5 Regeneron Pharmaceuticals Recent Development 11.2 Bayer HealthCare 11.2.1 Bayer HealthCare Company Details 11.2.2 Bayer HealthCare Business Overview 11.2.3 Bayer HealthCare Macular Degeneration (AMD) and Other Retinal Diseases Introduction 11.2.4 Bayer HealthCare Revenue in Macular Degeneration (AMD) and Other Retinal Diseases Business (2016-2021) 11.2.5 Bayer HealthCare Recent Development 11.3 Novartis 11.3.1 Novartis Company Details 11.3.2 Novartis Business Overview 11.3.3 Novartis Macular Degeneration (AMD) and Other Retinal Diseases Introduction 11.3.4 Novartis Revenue in Macular Degeneration (AMD) and Other Retinal Diseases Business (2016-2021) 11.3.5 Novartis Recent Development 11.4 Roche 11.4.1 Roche Company Details 11.4.2 Roche Business Overview 11.4.3 Roche Macular Degeneration (AMD) and Other Retinal Diseases Introduction 11.4.4 Roche Revenue in Macular Degeneration (AMD) and Other Retinal Diseases Business (2016-2021) 11.4.5 Roche Recent Development 11.5 Kanghong Pharma 11.5.1 Kanghong Pharma Company Details 11.5.2 Kanghong Pharma Business Overview 11.5.3 Kanghong Pharma Macular Degeneration (AMD) and Other Retinal Diseases Introduction 11.5.4 Kanghong Pharma Revenue in Macular Degeneration (AMD) and Other Retinal Diseases Business (2016-2021) 11.5.5 Kanghong Pharma Recent Development 11.6 Merck 11.6.1 Merck Company Details 11.6.2 Merck Business Overview 11.6.3 Merck Macular Degeneration (AMD) and Other Retinal Diseases Introduction 11.6.4 Merck Revenue in Macular Degeneration (AMD) and Other Retinal Diseases Business (2016-2021) 11.6.5 Merck Recent Development 11.7 Allergan 11.7.1 Allergan Company Details 11.7.2 Allergan Business Overview 11.7.3 Allergan Macular Degeneration (AMD) and Other Retinal Diseases Introduction 11.7.4 Allergan Revenue in Macular Degeneration (AMD) and Other Retinal Diseases Business (2016-2021) 11.7.5 Allergan Recent Development 11.8 Santen Pharmaceutical 11.8.1 Santen Pharmaceutical Company Details 11.8.2 Santen Pharmaceutical Business Overview 11.8.3 Santen Pharmaceutical Macular Degeneration (AMD) and Other Retinal Diseases Introduction 11.8.4 Santen Pharmaceutical Revenue in Macular Degeneration (AMD) and Other Retinal Diseases Business (2016-2021) 11.8.5 Santen Pharmaceutical Recent Development 11.9 GlaxoSmithKline Pharmaceuticals 11.9.1 GlaxoSmithKline Pharmaceuticals Company Details 11.9.2 GlaxoSmithKline Pharmaceuticals Business Overview 11.9.3 GlaxoSmithKline Pharmaceuticals Macular Degeneration (AMD) and Other Retinal Diseases Introduction 11.9.4 GlaxoSmithKline Pharmaceuticals Revenue in Macular Degeneration (AMD) and Other Retinal Diseases Business (2016-2021) 11.9.5 GlaxoSmithKline Pharmaceuticals Recent Development 11.10 Pfizer 11.10.1 Pfizer Company Details 11.10.2 Pfizer Business Overview 11.10.3 Pfizer Macular Degeneration (AMD) and Other Retinal Diseases Introduction 11.10.4 Pfizer Revenue in Macular Degeneration (AMD) and Other Retinal Diseases Business (2016-2021) 11.10.5 Pfizer Recent Development 11.11 Acucela 11.11.1 Acucela Company Details 11.11.2 Acucela Business Overview 11.11.3 Acucela Macular Degeneration (AMD) and Other Retinal Diseases Introduction 11.11.4 Acucela Revenue in Macular Degeneration (AMD) and Other Retinal Diseases Business (2016-2021) 11.11.5 Acucela Recent Development 11.12 Valent Pharmaceuticals 11.12.1 Valent Pharmaceuticals Company Details 11.12.2 Valent Pharmaceuticals Business Overview 11.12.3 Valent Pharmaceuticals Macular Degeneration (AMD) and Other Retinal Diseases Introduction 11.12.4 Valent Pharmaceuticals Revenue in Macular Degeneration (AMD) and Other Retinal Diseases Business (2016-2021) 11.12.5 Valent Pharmaceuticals Recent Development 11.13 IVERIC 11.13.1 IVERIC Company Details 11.13.2 IVERIC Business Overview 11.13.3 IVERIC Macular Degeneration (AMD) and Other Retinal Diseases Introduction 11.13.4 IVERIC Revenue in Macular Degeneration (AMD) and Other Retinal Diseases Business (2016-2021) 11.13.5 IVERIC Recent Development 12 Analyst's Viewpoints/Conclusions 13 Appendix 13.1 Research Methodology 13.1.1 Methodology/Research Approach 13.1.2 Data Source 13.2 Disclaimer 13.3 Author Details

List of Tables Table 1. Global Macular Degeneration (AMD) and Other Retinal Diseases Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027 Table 2. Key Players of Macular Degeneration Table 3. Key Players of Diabetic Macular Edema Table 4. Key Players of Diabetic Retinopathy(DR) Table 5. Key Players of Retinal Vein Occlusion Table 6. Key Players of Wet Age-Related Macular Degeneration (wAMD) Table 7. Key Players of Dry Age-Related Macular Degeneration (dAMD) Table 8. Key Players of Other Table 9. Global Macular Degeneration (AMD) and Other Retinal Diseases Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027 Table 10. Global Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027 Table 11. Global Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Regions (2016-2021) & (US$ Million) Table 12. Global Macular Degeneration (AMD) and Other Retinal Diseases Market Share by Regions (2016-2021) Table 13. Global Macular Degeneration (AMD) and Other Retinal Diseases Forecasted Market Size by Regions (2022-2027) & (US$ Million) Table 14. Global Macular Degeneration (AMD) and Other Retinal Diseases Market Share by Regions (2022-2027) Table 15. Macular Degeneration (AMD) and Other Retinal Diseases Market Trends Table 16. Macular Degeneration (AMD) and Other Retinal Diseases Market Drivers Table 17. Macular Degeneration (AMD) and Other Retinal Diseases Market Challenges Table 18. Macular Degeneration (AMD) and Other Retinal Diseases Market Restraints Table 19. Global Macular Degeneration (AMD) and Other Retinal Diseases Revenue by Players (2016-2021) & (US$ Million) Table 20. Global Macular Degeneration (AMD) and Other Retinal Diseases Market Share by Players (2016-2021) Table 21. Global Top Macular Degeneration (AMD) and Other Retinal Diseases Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Macular Degeneration (AMD) and Other Retinal Diseases as of 2020) Table 22. Ranking of Global Top Macular Degeneration (AMD) and Other Retinal Diseases Companies by Revenue (US$ Million) in 2020 Table 23. Global 5 Largest Players Market Share by Macular Degeneration (AMD) and Other Retinal Diseases Revenue (CR5 and HHI) & (2016-2021) Table 24. Key Players Headquarters and Area Served Table 25. Key Players Macular Degeneration (AMD) and Other Retinal Diseases Product Solution and Service Table 26. Date of Enter into Macular Degeneration (AMD) and Other Retinal Diseases Market Table 27. Mergers & Acquisitions, Expansion Plans Table 28. Global Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Type (2016-2021) (US$ Million) Table 29. Global Macular Degeneration (AMD) and Other Retinal Diseases Revenue Market Share by Type (2016-2021) Table 30. Global Macular Degeneration (AMD) and Other Retinal Diseases Forecasted Market Size by Type (2022-2027) (US$ Million) Table 31. Global Macular Degeneration (AMD) and Other Retinal Diseases Revenue Market Share by Type (2022-2027) & (US$ Million) Table 32. Global Macular Degeneration (AMD) and Other Retinal Diseases Market Size Share by Application (2016-2021) & (US$ Million) Table 33. Global Macular Degeneration (AMD) and Other Retinal Diseases Revenue Market Share by Application (2016-2021) Table 34. Global Macular Degeneration (AMD) and Other Retinal Diseases Forecasted Market Size by Application (2022-2027) (US$ Million) Table 35. Global Macular Degeneration (AMD) and Other Retinal Diseases Revenue Market Share by Application (2022-2027) & (US$ Million) Table 36. North America Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Type (2016-2021) (US$ Million) Table 37. North America Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Type (2022-2027) & (US$ Million) Table 38. North America Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Application (2016-2021) (US$ Million) Table 39. North America Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Application (2022-2027) & (US$ Million) Table 40. North America Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Country (2016-2021) & (US$ Million) Table 41. North America Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Country (2022-2027) & (US$ Million) Table 42. Europe Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Type (2016-2021) (US$ Million) Table 43. Europe Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Type (2022-2027) & (US$ Million) Table 44. Europe Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Application (2016-2021) (US$ Million) Table 45. Europe Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Application (2022-2027) & (US$ Million) Table 46. Europe Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Country (2016-2021) & (US$ Million) Table 47. Europe Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Country (2022-2027) & (US$ Million) Table 48. Asia-Pacific Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Type (2016-2021) (US$ Million) Table 49. Asia-Pacific Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Type (2022-2027) & (US$ Million) Table 50. Asia-Pacific Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Application (2016-2021) (US$ Million) Table 51. Asia-Pacific Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Application (2022-2027) & (US$ Million) Table 52. Asia-Pacific Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Region (2016-2021) & (US$ Million) Table 53. Asia-Pacific Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Region (2022-2027) & (US$ Million) Table 54. Latin America Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Type (2016-2021) (US$ Million) Table 55. Latin America Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Type (2022-2027) & (US$ Million) Table 56. Latin America Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Application (2016-2021) (US$ Million) Table 57. Latin America Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Application (2022-2027) & (US$ Million) Table 58. Latin America Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Country (2016-2021) & (US$ Million) Table 59. Latin America Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Country (2022-2027) & (US$ Million) Table 60. Middle East & Africa Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Type (2016-2021) (US$ Million) Table 61. Middle East & Africa Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Type (2022-2027) & (US$ Million) Table 62. Middle East & Africa Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Application (2016-2021) (US$ Million) Table 63. Middle East & Africa Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Application (2022-2027) & (US$ Million) Table 64. Middle East & Africa Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Country (2016-2021) & (US$ Million) Table 65. Middle East & Africa Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Country (2022-2027) & (US$ Million) Table 66. Regeneron Pharmaceuticals Company Details Table 67. Regeneron Pharmaceuticals Business Overview Table 68. Regeneron Pharmaceuticals Macular Degeneration (AMD) and Other Retinal Diseases Product Table 69. Regeneron Pharmaceuticals Revenue in Macular Degeneration (AMD) and Other Retinal Diseases Business (2016-2021) & (US$ Million) Table 70. Regeneron Pharmaceuticals Recent Development Table 71. Bayer HealthCare Company Details Table 72. Bayer HealthCare Business Overview Table 73. Bayer HealthCare Macular Degeneration (AMD) and Other Retinal Diseases Product Table 74. Bayer HealthCare Revenue in Macular Degeneration (AMD) and Other Retinal Diseases Business (2016-2021) & (US$ Million) Table 75. Bayer HealthCare Recent Development Table 76. Novartis Company Details Table 77. Novartis Business Overview Table 78. Novartis Macular Degeneration (AMD) and Other Retinal Diseases Product Table 79. Novartis Revenue in Macular Degeneration (AMD) and Other Retinal Diseases Business (2016-2021) & (US$ Million) Table 80. Novartis Recent Development Table 81. Roche Company Details Table 82. Roche Business Overview Table 83. Roche Macular Degeneration (AMD) and Other Retinal Diseases Product Table 84. Roche Revenue in Macular Degeneration (AMD) and Other Retinal Diseases Business (2016-2021) & (US$ Million) Table 85. Roche Recent Development Table 86. Kanghong Pharma Company Details Table 87. Kanghong Pharma Business Overview Table 88. Kanghong Pharma Macular Degeneration (AMD) and Other Retinal Diseases Product Table 89. Kanghong Pharma Revenue in Macular Degeneration (AMD) and Other Retinal Diseases Business (2016-2021) & (US$ Million) Table 90. Kanghong Pharma Recent Development Table 91. Merck Company Details Table 92. Merck Business Overview Table 93. Merck Macular Degeneration (AMD) and Other Retinal Diseases Product Table 94. Merck Revenue in Macular Degeneration (AMD) and Other Retinal Diseases Business (2016-2021) & (US$ Million) Table 95. Merck Recent Development Table 96. Allergan Company Details Table 97. Allergan Business Overview Table 98. Allergan Macular Degeneration (AMD) and Other Retinal Diseases Product Table 99. Allergan Revenue in Macular Degeneration (AMD) and Other Retinal Diseases Business (2016-2021) & (US$ Million) Table 100. Allergan Recent Development Table 101. Santen Pharmaceutical Company Details Table 102. Santen Pharmaceutical Business Overview Table 103. Santen Pharmaceutical Revenue in Macular Degeneration (AMD) and Other Retinal Diseases Business (2016-2021) & (US$ Million) Table 104. Santen Pharmaceutical Recent Development Table 105. GlaxoSmithKline Pharmaceuticals Company Details Table 106. GlaxoSmithKline Pharmaceuticals Business Overview Table 107. GlaxoSmithKline Pharmaceuticals Macular Degeneration (AMD) and Other Retinal Diseases Product Table 108. GlaxoSmithKline Pharmaceuticals Revenue in Macular Degeneration (AMD) and Other Retinal Diseases Business (2016-2021) & (US$ Million) Table 109. GlaxoSmithKline Pharmaceuticals Recent Development Table 110. Pfizer Company Details Table 111. Pfizer Business Overview Table 112. Pfizer Macular Degeneration (AMD) and Other Retinal Diseases Product Table 113. Pfizer Revenue in Macular Degeneration (AMD) and Other Retinal Diseases Business (2016-2021) & (US$ Million) Table 114. Pfizer Recent Development Table 115. Acucela Company Details Table 116. Acucela Business Overview Table 117. Acucela Macular Degeneration (AMD) and Other Retinal Diseases Product Table 118. Acucela Revenue in Macular Degeneration (AMD) and Other Retinal Diseases Business (2016-2021) & (US$ Million) Table 119. Acucela Recent Development Table 120. Valent Pharmaceuticals Company Details Table 121. Valent Pharmaceuticals Business Overview Table 122. Valent Pharmaceuticals Macular Degeneration (AMD) and Other Retinal Diseases Product Table 123. Valent Pharmaceuticals Revenue in Macular Degeneration (AMD) and Other Retinal Diseases Business (2016-2021) & (US$ Million) Table 124. Valent Pharmaceuticals Recent Development Table 125. IVERIC Company Details Table 126. IVERIC Business Overview Table 127. IVERIC Macular Degeneration (AMD) and Other Retinal Diseases Product Table 128. IVERIC Revenue in Macular Degeneration (AMD) and Other Retinal Diseases Business (2016-2021) & (US$ Million) Table 129. IVERIC Recent Development Table 130. Research Programs/Design for This Report Table 131. Key Data Information from Secondary Sources Table 132. Key Data Information from Primary Sources List of Figures Figure 1. Global Macular Degeneration (AMD) and Other Retinal Diseases Market Share by Type: 2020 VS 2027 Figure 2. Macular Degeneration Features Figure 3. Diabetic Macular Edema Features Figure 4. Diabetic Retinopathy(DR) Features Figure 5. Retinal Vein Occlusion Features Figure 6. Wet Age-Related Macular Degeneration (wAMD) Features Figure 7. Dry Age-Related Macular Degeneration (dAMD) Features Figure 8. Other Features Figure 9. Global Macular Degeneration (AMD) and Other Retinal Diseases Market Share by Application: 2020 VS 2027 Figure 10. Hospital Case Studies Figure 11. Clinic Case Studies Figure 12. Other Case Studies Figure 13. Macular Degeneration (AMD) and Other Retinal Diseases Report Years Considered Figure 14. Global Macular Degeneration (AMD) and Other Retinal Diseases Market Size (US$ Million), Year-over-Year: 2016-2027 Figure 15. Global Macular Degeneration (AMD) and Other Retinal Diseases Market Size (US$ Million), 2016 VS 2021 VS 2027 Figure 16. Global Macular Degeneration (AMD) and Other Retinal Diseases Market Share by Regions: 2020 VS 2027 Figure 17. Global Macular Degeneration (AMD) and Other Retinal Diseases Market Share by Regions (2022-2027) Figure 18. Global Macular Degeneration (AMD) and Other Retinal Diseases Market Share by Players in 2020 Figure 19. Global Top Macular Degeneration (AMD) and Other Retinal Diseases Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Macular Degeneration (AMD) and Other Retinal Diseases as of 2020 Figure 20. The Top 10 and 5 Players Market Share by Macular Degeneration (AMD) and Other Retinal Diseases Revenue in 2020 Figure 21. Global Macular Degeneration (AMD) and Other Retinal Diseases Revenue Market Share by Type (2016-2021) Figure 22. Global Macular Degeneration (AMD) and Other Retinal Diseases Revenue Market Share by Type (2022-2027) Figure 23. North America Macular Degeneration (AMD) and Other Retinal Diseases Market Size YoY Growth (2016-2027) & (US$ Million) Figure 24. North America Macular Degeneration (AMD) and Other Retinal Diseases Market Share by Type (2016-2027) Figure 25. North America Macular Degeneration (AMD) and Other Retinal Diseases Market Share by Application (2016-2027) Figure 26. North America Macular Degeneration (AMD) and Other Retinal Diseases Market Share by Country (2016-2027) Figure 27. United States Macular Degeneration (AMD) and Other Retinal Diseases Market Size YoY Growth (2016-2027) & (US$ Million) Figure 28. Canada Macular Degeneration (AMD) and Other Retinal Diseases Market Size YoY Growth (2016-2027) & (US$ Million) Figure 29. Europe Macular Degeneration (AMD) and Other Retinal Diseases Market Size YoY Growth (2016-2027) & (US$ Million) Figure 30. Europe Macular Degeneration (AMD) and Other Retinal Diseases Market Share by Type (2016-2027) Figure 31. Europe Macular Degeneration (AMD) and Other Retinal Diseases Market Share by Application (2016-2027) Figure 32. Europe Macular Degeneration (AMD) and Other Retinal Diseases Market Share by Country (2016-2027) Figure 33. Germany Macular Degeneration (AMD) and Other Retinal Diseases Market Size YoY Growth (2016-2027) & (US$ Million) Figure 34. France Macular Degeneration (AMD) and Other Retinal Diseases Market Size YoY Growth (2016-2027) & (US$ Million) Figure 35. U.K. Macular Degeneration (AMD) and Other Retinal Diseases Market Size YoY Growth (2016-2027) & (US$ Million) Figure 36. Italy Macular Degeneration (AMD) and Other Retinal Diseases Market Size YoY Growth (2016-2027) & (US$ Million) Figure 37. Russia Macular Degeneration (AMD) and Other Retinal Diseases Market Size YoY Growth (2016-2027) & (US$ Million) Figure 38. Nordic Macular Degeneration (AMD) and Other Retinal Diseases Market Size YoY Growth (2016-2027) & (US$ Million) Figure 39. Asia-Pacific Macular Degeneration (AMD) and Other Retinal Diseases Market Size YoY Growth (2016-2027) & (US$ Million) Figure 40. Asia-Pacific Macular Degeneration (AMD) and Other Retinal Diseases Market Share by Type (2016-2027) Figure 41. Asia-Pacific Macular Degeneration (AMD) and Other Retinal Diseases Market Share by Application (2016-2027) Figure 42. Asia-Pacific Macular Degeneration (AMD) and Other Retinal Diseases Market Share by Region (2016-2027) Figure 43. China Macular Degeneration (AMD) and Other Retinal Diseases Market Size YoY Growth (2016-2027) & (US$ Million) Figure 44. Japan Macular Degeneration (AMD) and Other Retinal Diseases Market Size YoY Growth (2016-2027) & (US$ Million) Figure 45. South Korea Macular Degeneration (AMD) and Other Retinal Diseases Market Size YoY Growth (2016-2027) & (US$ Million) Figure 46. Southeast Asia Macular Degeneration (AMD) and Other Retinal Diseases Market Size YoY Growth (2016-2027) & (US$ Million) Figure 47. India Macular Degeneration (AMD) and Other Retinal Diseases Market Size YoY Growth (2016-2027) & (US$ Million) Figure 48. Australia Macular Degeneration (AMD) and Other Retinal Diseases Market Size YoY Growth (2016-2027) & (US$ Million) Figure 49. Latin America Macular Degeneration (AMD) and Other Retinal Diseases Market Size YoY Growth (2016-2027) & (US$ Million) Figure 50. Latin America Macular Degeneration (AMD) and Other Retinal Diseases Market Share by Type (2016-2027) Figure 51. Latin America Macular Degeneration (AMD) and Other Retinal Diseases Market Share by Application (2016-2027) Figure 52. Latin America Macular Degeneration (AMD) and Other Retinal Diseases Market Share by Country (2016-2027) Figure 53. Mexico Macular Degeneration (AMD) and Other Retinal Diseases Market Size YoY Growth (2016-2027) & (US$ Million) Figure 54. Brazil Macular Degeneration (AMD) and Other Retinal Diseases Market Size YoY Growth (2016-2027) & (US$ Million) Figure 55. Middle East & Africa Macular Degeneration (AMD) and Other Retinal Diseases Market Size YoY Growth (2016-2027) & (US$ Million) Figure 56. Middle East & Africa Macular Degeneration (AMD) and Other Retinal Diseases Market Share by Type (2016-2027) Figure 57. Middle East & Africa Macular Degeneration (AMD) and Other Retinal Diseases Market Share by Application (2016-2027) Figure 58. Middle East & Africa Macular Degeneration (AMD) and Other Retinal Diseases Market Share by Country (2016-2027) Figure 59. Turkey Macular Degeneration (AMD) and Other Retinal Diseases Market Size YoY Growth (2016-2027) & (US$ Million) Figure 60. Saudi Arabia Macular Degeneration (AMD) and Other Retinal Diseases Market Size YoY Growth (2016-2027) & (US$ Million) Figure 61. UAE Macular Degeneration (AMD) and Other Retinal Diseases Market Size YoY Growth (2016-2027) & (US$ Million) Figure 62. Regeneron Pharmaceuticals Revenue Growth Rate in Macular Degeneration (AMD) and Other Retinal Diseases Business (2016-2021) Figure 63. Bayer HealthCare Revenue Growth Rate in Macular Degeneration (AMD) and Other Retinal Diseases Business (2016-2021) Figure 64. Novartis Revenue Growth Rate in Macular Degeneration (AMD) and Other Retinal Diseases Business (2016-2021) Figure 65. Roche Revenue Growth Rate in Macular Degeneration (AMD) and Other Retinal Diseases Business (2016-2021) Figure 66. Kanghong Pharma Revenue Growth Rate in Macular Degeneration (AMD) and Other Retinal Diseases Business (2016-2021) Figure 67. Merck Revenue Growth Rate in Macular Degeneration (AMD) and Other Retinal Diseases Business (2016-2021) Figure 68. Allergan Revenue Growth Rate in Macular Degeneration (AMD) and Other Retinal Diseases Business (2016-2021) Figure 69. Santen Pharmaceutical Revenue Growth Rate in Macular Degeneration (AMD) and Other Retinal Diseases Business (2016-2021) Figure 70. GlaxoSmithKline Pharmaceuticals Revenue Growth Rate in Macular Degeneration (AMD) and Other Retinal Diseases Business (2016-2021) Figure 71. Pfizer Revenue Growth Rate in Macular Degeneration (AMD) and Other Retinal Diseases Business (2016-2021) Figure 72. Acucela Revenue Growth Rate in Macular Degeneration (AMD) and Other Retinal Diseases Business (2016-2021) Figure 73. Valent Pharmaceuticals Revenue Growth Rate in Macular Degeneration (AMD) and Other Retinal Diseases Business (2016-2021) Figure 74. IVERIC Revenue Growth Rate in Macular Degeneration (AMD) and Other Retinal Diseases Business (2016-2021) Figure 75. Bottom-up and Top-down Approaches for This Report Figure 76. Data Triangulation Figure 77. Key Executives Interviewed

Regeneron Pharmaceuticals Bayer HealthCare Novartis Roche Kanghong Pharma Merck Allergan Santen Pharmaceutical GlaxoSmithKline Pharmaceuticals Pfizer Acucela Valent Pharmaceuticals IVERIC